Targeted and Stimulus-Responsive Nanomedicines for the Treatment of Central Nervous System (CNS) Disorders
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: closed (31 October 2021) | Viewed by 12749
Special Issue Editors
Interests: drug delivery; nanoparticles; nanogels; polymeric nanocarriers; sustained release; blood–brain barrier (BBB); drug permeability; transcytosis mechanisms; BBB receptors; endothelial cells; IVIVC
Interests: drug delivery; gene therapy; liposomes; lipid nanoparticles; stimuli-responsive nanoparticles; targeting strategies; aptamers; DNA nanotechnology; pH-responsive; molecular tweezers; switchable lipids; cancer; chronic lung disease
Special Issue Information
Dear Colleagues,
Despite tremendous efforts to create innovative treatments, CNS diseases are still among the diseases with the poorest outcomes for those affected. A clinical diagnosis of illnesses such as glioma, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis and many others strikes patients with a deadly sentence on a daily basis, and the current pharmaceutical tools to alleviate their medical condition are still limited in number and mostly palliative.
When the nanotechnology wave overwhelmed the pharmaceutical field some thirty years ago, there was no limit to researchers’ expectations regarding CNS nanotreatments, with major progress made in deciphering the fate of nanoparticles in the blood circulation; however, to date, the presence of the restrictive blood–brain barrier (BBB) still limits the effective translocation of nanocarriers into the brain.
New strategies have to be designed to target and tackle the specificities of the BBB and the pathological conditions of CNS disorders. For instance, what are the specific translocation pathways used by nanocarriers to cross the BBB? What is the fate of nanocarriers in BBB endothelial cells according to their materials and/or targeting strategy ? How can we improve both BBB translocation and brain cellular targeting? How can we exploit pathological microenvironment to improve specific drug or gene targeting?
To answer those questions, we welcome contributions regarding:
- Methodologies to synthetize and characterize nanomedicines, lipid-, polymer- or hydrid-based nanocarriers for therapeutic, diagnostic or theranostic purposes;
- In vitro and in vivo proof-of-concepts for detecting or targeting brain disorders, i.e., using ligands, aptamers, peptides or stimuli-responsive strategies;
- Reports of novel receptors and pathways specifically involved in nanocarrier translocation to the CNS.
Prof. Dr. Valérie Gaëlle Roullin
Prof. Jeanne Leblond Chain
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- brain disease
- brain pathology
- CNS disorder
- brain targeting
- nanoparticles
- nanocarriers
- nanomedicines
- transcytosis
- translocation
- blood–brain barrier
- diagnosis
- therapy
- theranostic
- lipid nanoparticles
- polymer nanoparticles
- liposomes
- active targeting
- aptamers
- stimulus-responsive
- gene delivery
- combined therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
